EGFR and cancer: In humans with a loss-of-function mutation in the epidermal growth factor receptor (EGFR) or ADAM17, an EGFR ligand sheddase, as well as patients undergoing long-term EGFR-inhibitor treatment during targeted cancer therapy, experience chronic hair and skin inflammation, which can be accompanied by scarring hair loss (Earl et al, 2020; Franzke et al, 2012; Nowaczyk et al, 2023; Satoh et al, 2020; Yang et al, 2011).